The purpose of this study is to understand the effects of intrathecal ziconotide (an
experimental pain medication) when the dose is slowly increased over a 3-week period in
patients with severe chronic pain. During the weaning phase, the study will also gather
information about switching from other intrathecal or IT medication (slowly pumped directly
into the space around the spine) to other systemic pain medication (by mouth or through the
skin using a patch). After being weaned off current IT medication, patients will be placed on
IT ziconotide or placebo (non-active substance) as well as being allowed a stable dose of
systemic pain medications.
Patients who complete this study may be eligible for long-term ziconotide therapy via
extension protocol ELN92045-352.
Patient Registry of Intrathecal Ziconotide Management(PRIZM)
The objectives of this study are to evaluate the effectiveness, long-term safety,
tolerability, satisfaction with treatment, and health-related quality of life (HRQoL)
associated with Intrathecal PRIALT use for severe chronic pain of varying etiologies.
Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy
This is a phase 4 study being conducted at the Ohio State University Department of Neurology
Multiple Sclerosis Research Program. The purpose of the study is to administer a single shot
of intrathecal (injection into the space surrounding the spinal cord via a lumbar puncture or
spinal tap) ziconotide as a test dose to patients who have chronic painful myelopathy (pain
from spinal cord damage) or painful peripheral neuropathy (pain from nerve damage) that has
not responded to other pain medicines.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.